American Society of Hirudotherapy

Research progress in hirudin fusion protein--review

Review article published in Zhongguo shi yan xue ye xue za zhi (2007)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewSalivary PharmacologyGenomics & ProteomicsZhang C et al. · Zhongguo shi yan xue ye xue za zhi, 2007

Abstract

Natural hirudin extracted from the secretion of medical leech salivary gland is a single-chain peptide containing 65 aminoacid residues with molecular weight of 7000 D, and exists in three isomers of HV1, HV2 and HV3. Hirudin possesses three disulfide bridges forming the structure of core cyclic peptides, which binds to the catalytic site of thrombin so as to inhibit the catalysis of thrombin. Its c-terminus rich in acidic aminoacid residues possesses hydrophilicity, and is free on the molecular surface, and can bind with fibrin recognition site of hirudin. The minimal segment of 12 - 16 C-terminal acidic residues keeps the minimal activity of anti-thrombosis. Thus, hirudin, as a potent and specific inhibitor of thrombin, can be used to protect from and to treat clinically thrombosis. As it has some disadvantages such as short half-life, bleeding side-effect and mono-function, and so on, hirudin has been fused with some other functional proteins in recent years. The obtained fusion proteins can prolong the half life of hirudin, or relieve it bleeding side effect, or bring new functions, such as thrombolysis, inhibiting the platelet aggregation, targeting specifically. The research progress in hirudin fusion protein was summarized in this review.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal ArticleReview
Indexed MeSH termsAnticoagulantsDelayed-Action PreparationsDrug Delivery SystemsGlucokinaseHirudinsHumansPlatelet Aggregation InhibitorsRecombinant Fusion ProteinsUrokinase-Type Plasminogen Activator

Summary

This review summarizes hirudin fusion proteins: because natural hirudin has a short half-life, bleeding effects and single function, it has been fused with other proteins to prolong half-life, reduce bleeding, or add thrombolytic, antiplatelet or targeting functions.

Why This Matters for Hirudotherapy

This review summarizes work on hirudin, the leech salivary-gland anticoagulant described here as a 65-residue, ~7000 D peptide (isoforms HV1-HV3) that directly inhibits thrombin, and surveys efforts to fuse it with other functional proteins to extend its short half-life, reduce bleeding side effects, or add functions such as thrombolysis, platelet-aggregation inhibition, and specific targeting. It directly illustrates the medicinal-leech-secretome drug-discovery story: a single natural leech molecule has seeded a family of engineered anticoagulant therapeutics. The caveat is that this is a narrative review of others' research and an account of engineered fusion proteins rather than whole-leech therapy, so it reports design rationale and progress, not pooled clinical outcomes.

Citation

Reference (Vancouver style)

Zhang CL, Yu AP, Jin JD, Wu CT. [Research progress in hirudin fusion protein--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15(1):215-218. PMID: 17490558

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: March 18, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.